Moreover, when tumor cells sustain DNA damage response pathways or lack cGAS, the combination of STING agonists and PARP inhibitors can be utilized to further bolster anti-tumor immunity, effectively broadening the applicability of PARP inhibitors (Figure 2). The gene discussed is CGAS; the disease is neoplasm.